☀️     🌓

Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

Tiotropium versus Salmeterol in COPD

The New England Journal of Medicine has published the results of a trial that aimed to assess the efficacy of tiotropium versus salmeterol in preventing exacerbations in patients with chronic obstructive pulmonary disease (COPD). The study is being referred to as the Prevention Of Exacerbations with Tiotropium in COPD (POET-COPD) trial.

The trial recruited 7,376 patients with moderate to very severe COPD and a history of exacerbations in the previous year. The trial was randomised and double blind by design. 3,707 patients were assigned to treatment with 18 micrograms of tiotropium daily while 3,669 patients were assigned to treatment with 50 micrograms of salmeterol twice daily via a metered dose aerosol inhaler. To maintain adequate blinding, patients were issued with a corresponding placebo device.

The study ran for 1 year with a primary end point of time to first exacerbation. Secondary endpoints included annual number of moderate to severe exacerbations and annual number of severe exacerbations.

Treatment with tiotropium increased the average time to a first exacerbation from 145 days to 187 days. It also increased the time to a first severe exacerbation, decreased the annual number of moderate to severe exacerbations from 0.72 to 0.64 (rate ratio 0.89, 95% CI, 0.83 - 0.96, P=0.002) and decreased the annual number of severe exacerbations from 0.13 to 0.09 (rate ratio 0.73, 95% CI, 0.66 to 0.82, P<0.001).

The authors conclude that, "in patients with moderate-to-very-severe COPD, tiotropium is more effective than salmeterol in preventing exacerbations". Adverse event and discontinuation rates were similar in both study groups.

This study does provide some valuable data however there are limitations. Tiotropium was compared to salmeterol in a metered dose aerosol inhaler so it is unclear how dry power device would compare. Also, the study was not of long enough duration to assess if the reduction in exacerbations produced an increase in life expectancy.

Action: Clinicians should be aware of this study. The current NICE guideline for COPD places tiotropium (a long acting muscarinic antagonist or LAMA) and salmeterol (a long acting beta agonist or LABA) at the same level. Based on this study clinicians may wish to consider using a LAMA in favour of a LABA where appropriate.

Share 'Tiotropium versus Salmeterol in COPD' by emailShare 'Tiotropium versus Salmeterol in COPD' on FacebookShare 'Tiotropium versus Salmeterol in COPD' on TwitterShare 'Tiotropium versus Salmeterol in COPD' on LinkedInShare 'Tiotropium versus Salmeterol in COPD' on reddit

Drug Safety Update - April 2011

The Medicines and Healthcare products Regulatory Agency (MHRA) has published Drug Safety Update for April 2011 (PDF).

This issue contains drug safety information advising stavudine (Zerit®) should be only used as a treatment for HIV infection when there are no appropriate alternatives, and for the shortest possible time. This is because of an increased risk of potentially severe adverse events as a result of mitochondrial toxicity. It is estimated that there are currently 160 patients in the UK using stavudine. These patients should be reviewed and switched to an appropriate alternative as soon as possible.

The hot topic section reminds clinicians of the need to monitor and manage weight, glucose and lipid levels in patients who are prescribed second generation (atypical) antipsychotics. These risk factors should be managed in line with the recommendations issued by NICE in order to reduce the risk of premature natural death.

Action: Clinicians will find this publication to be a useful review of current issues in drug safety.

Share 'Drug Safety Update - April 2011' by emailShare 'Drug Safety Update - April 2011' on FacebookShare 'Drug Safety Update - April 2011' on TwitterShare 'Drug Safety Update - April 2011' on LinkedInShare 'Drug Safety Update - April 2011' on reddit

Newer Posts »

Prescribing Advice for GPs is powered by ClassicPress.
Connect to our RSS or Atom Feeds.